{"doi":"10.9740/mhc.2015.03.088","title":"Successful clozapine rechallenge following clozapine-induced neuroleptic malignant syndrome","abstract":"<jats:title>Abstract</jats:title>\n               <jats:p>Neuroleptic malignant syndrome (NMS) is a potential life-threatening adverse effect of antipsychotics. Characteristic signs and symptoms of NMS include hyperthermia, muscle rigidity, altered mental status, and autonomic instability. Treatment of NMS includes discontinuation of any antipsychotic or other potentially offending agents. This report describes the details of a patient diagnosed with NMS induced by clozapine with subsequent successful rechallenge. Given limited therapeutic options for patients with treatment-resistant schizophrenia, clinicians should be cognizant of potential risks but aware of the possibility of successful rechallenge with clozapine.</jats:p>","journal":"Mental Health Clinician","year":2015,"id":32518,"datarank":0.21810129564103417,"base_score":1.0986122886681096,"endowment":1.0986122886681096,"self_citation_contribution":0.16479184330021646,"citation_network_contribution":0.053309452340817715,"self_endowment_contribution":0.16479184330021646,"citer_contribution":0.053309452340817715,"corpus_percentile":null,"corpus_rank":null,"citation_count":2,"citer_count":2,"citers_with_citation_signal":1,"citers_with_endowment":1,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":171931,"name":"Clint Ross","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"base_score":1.0986122886681096,"endowment":1.0986122886681096,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"24523987","pmcid":null,"openalex_id":"https://openalex.org/W1980073550","authors":[],"funders":[],"total_grants":0,"fwci":0.2095,"citation_percentile":0.5712325,"influential_citations":0,"citation_trend":[{"year":2017,"count":1},{"year":2024,"count":1}],"oa_status":"gold","license":"cc-by-nc","oa_locations":[{"url":"https://doi.org/10.9740/mhc.2015.03.088","host_type":"journal"},{"url":"https://doi.org/10.9740/mhc.2015.03.088","host_type":"GOLD"},{"url":"https://doi.org/10.9740/mhc.2015.03.088","host_type":"publisher"},{"url":"http://meridian.allenpress.com/mhc/article-pdf/5/2/88/2095152/mhc_2015_03_088.pdf","host_type":"publisher"}],"fields_of_study":["Electroconvulsive Therapy Studies","Treatment of Major Depression","Schizophrenia research and treatment","Medicine"],"mesh_terms":[],"keywords":["Clozapine","Neuroleptic malignant syndrome","Medicine","Discontinuation","Antipsychotic","Adverse effect","Schizophrenia (object-oriented programming)","Psychosis","Intensive care medicine","Psychiatry","Anesthesia","Internal medicine"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-06-09T13:08:46.071230Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}